Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-05-25

FDA Approved: AMELUZ — Supplemental Application (Biofrontera Inc.)

View source ↗

Summary

The FDA approved a supplemental application for AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE) from Biofrontera Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)

Snippet

SUPPL AP for AMELUZ (AMINOLEVULINIC ACID HYDROCHLORIDE)